About MS
Newly Diagnosed
Get Involved
About MSNZ
Contact Us



Clinical Trial now recruiting for Secondary Progressive MS

Clozapine and risperidone are currently used to treat mental illnesses but have been shown to have anti-inflammatory effects in the brain and therefore may also be useful for treating MS.

The study is being run in Wellington and is currently looking for participants who:

  • Have secondary progressive multiple sclerosis
  • Are aged 18 – 70 years
  • Have an expanded disability status score of 3.5 to 6.0

For more information see here


NZ MS Care Survey - Can you help us shape a fair future?

Multiple Sclerosis New Zealand would like to hear more about you, your life with MS and how you experience the health services in NZ.

We want you to help inform us about what the needs are within the MS Community in NZ and how we can work and advocate to help improve services.

See here for more information

Take the survey today

MS Treatments Aubagio and Tecfidera Now Funded in NZ by PHARMAC

MSNZ welcomes PHARMAC’s decision to fund two new first-line treatments for relapsing- remitting forms of Multiple Sclerosis.

The Multiple Sclerosis Society of New Zealand (MSNZ) welcomes PHARMAC’s decision to fund two new first-line treatments for relapsing-remitting forms of MS.

The new treatments: dimethyl fumarate (Tecfidera) supplied by Biogen NZ and teriflunomide (Aubagio) supplied by Sanofi-Aventis NZ will be funded in the community and in DHB hospitals, subject to the same restrictions that apply to natalizumab (Tysabri) and fingolimod (Gilenya).

Click Here for more information

MS Regional Societies and Field Worker Service

If you would like further information and support you can contact your Regional Society directly. All our Regional Socieites employ skilled and experienced Field Workers who are available to you and your family and carers to provide on-going support, information and advice.

Contact your nearest regional MS Society





Multiple Sclerosis New Zealand

The Multiple Sclerosis Society of New Zealand (Inc) is a non-profit organisation formed to provide on-going support, education and advocacy for people with MS and their support networks.  It also aims to educate the general public, employers and health professionals about MS and actively funds key research into the condition.  The Society was formed in 1967 and today there are 18 Regional Societies from Northland to Southland supported through advice, education and materials by the National Office.